VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 93 filers reported holding VERVE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 4.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,183,430 | -28.0% | 466,322 | +1.8% | 0.00% | -50.0% |
| Q2 2023 | $8,591,963 | +47.6% | 458,238 | +13.5% | 0.00% | +100.0% |
| Q1 2023 | $5,819,378 | -24.8% | 403,563 | +0.9% | 0.00% | -50.0% |
| Q4 2022 | $7,737,349 | -42.1% | 399,863 | +2.8% | 0.00% | -33.3% |
| Q3 2022 | $13,358,000 | +211.2% | 388,916 | +38.4% | 0.00% | +200.0% |
| Q2 2022 | $4,292,000 | -32.7% | 280,915 | +0.5% | 0.00% | 0.0% |
| Q1 2022 | $6,378,000 | +19.6% | 279,499 | +93.3% | 0.00% | 0.0% |
| Q4 2021 | $5,331,000 | -19.0% | 144,585 | +3.2% | 0.00% | 0.0% |
| Q3 2021 | $6,584,000 | – | 140,091 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |